These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14728944)

  • 1. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
    Wildiers H; Ahmed B; Guetens G; De Boeck G; de Bruijn EA; Landuyt W; van Oosterom AT
    Eur J Cancer; 2004 Jan; 40(2):284-90. PubMed ID: 14728944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.
    Wildiers H; Ahmed B; Guetens G; De Boeck G; De Bruijn EA; Landuyt W; Van Oosterom AT
    Anticancer Res; 2003; 23(5A):4055-9. PubMed ID: 14666718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.
    Li L; Rojiani AM; Siemann DW
    Acta Oncol; 2002; 41(1):91-7. PubMed ID: 11990525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
    Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
    Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
    Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
    Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CPT-11 in combination with other anti-cancer agents in culture.
    Kano Y; Suzuki K; Akutsu M; Suda K; Inoue Y; Yoshida M; Sakamoto S; Miura Y
    Int J Cancer; 1992 Feb; 50(4):604-10. PubMed ID: 1537625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S; Rustum YM
    Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
    Mans DR; Grivicich I; Peters GJ; Schwartsmann G
    Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
    Danks MK; Morton CL; Pawlik CA; Potter PM
    Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas.
    Landuyt W; Verdoes O; Darius DO; Drijkoningen M; Nuyts S; Theys J; Stockx L; Wynendaele W; Fowler JF; Maleux G; Van den Bogaert W; Anné J; van Oosterom A; Lambin P
    Eur J Cancer; 2000 Sep; 36(14):1833-43. PubMed ID: 10974632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
    Maeda Y; Hamada A; Sanematsu E; Sasaki JI; Yokoo K; Hira A; Saito H
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):953-9. PubMed ID: 19697031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines.
    Mori H; Sawairi M; Itoh N; Hanabayashi T; Kondoh H; Tamaya T
    Anticancer Drugs; 1991 Oct; 2(5):469-74. PubMed ID: 1804390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
    Siemann DW; Mercer E; Lepler S; Rojiani AM
    Int J Cancer; 2002 May; 99(1):1-6. PubMed ID: 11948484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
    Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
    Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
    Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
    Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.